Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

VelaLabs Announces Strategic Partnership with EarlyHealth Group to Support Biological Drugs Development

VIENNA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- VelaLabs GmbH, a leading provider of analytical and quality services for biopharmaceutical development, has signed a Memorandum of Understanding (MoU) with EarlyHealth Group to establish comprehensive solutions for the development of advanced biological drugs.

Under the agreement, EarlyHealth Group will manage the supply of clinical trial materials, packaging and labeling, logistics, and early access programs. VelaLabs will complement this offering with advanced characterization and quality control (QC) testing of biomolecules, delivering a complete package for sponsors and Contract Research Organizations (CROs).

20241212_161127

“This partnership with EarlyHealth Group aligns perfectly with VelaLabs’ commitment to provide a comprehensive service platform to meet the rigorous demands of biosimilar development, ensuring timely and high-quality outcomes for the leading biosimilar companies of today,” said Andreas Nechansky, Chief Executive Officer of VelaLabs.

“Our collaboration with VelaLabs reinforces EarlyHealth Group’s mission to deliver tailored solutions within our clinical research portfolio,” said Dr. Danny Renout, Chief Executive Officer, “and through combining our expertise with VelaLabs’ renowned laboratory capabilities, we are able to fully support our customers drug development.”

This strategic partnership underlines both companies’ shared vision of supporting the pharmaceutical and biotech industries with specialized services, ultimately advancing the development and accessibility of biological drugs worldwide.

About VelaLabs
Founded in 2006, VelaLabs is a GLP- and GMP-certified, contract research and analytics laboratories, supporting pharmaceutical and biotech companies in the development, QC testing and QP release of biosimilars, new biological drugs, and Advanced Therapy Medicinal Products ATMPs. VelaLabs is part of the Tentamus Group, a Germany-based organization with 4,000 employees and overseeing 100 laboratories worldwide.

For more information, visit: www.vela-labs.at
For more information on Tentamus Group, visit: https://www.tentamus.com

About EarlyHealth Group
EarlyHealth Group is a global pharmaceutical company dedicated to improving healthcare accessibility through innovative product development and market access solutions. With roots dating back to 1984 in California, EarlyHealth Group has grown into a global leader with its head office in Dubai and operations spanning over 40 locations worldwide. The company offers a full range of clinical trial services, early access programs, and supply chain solutions to the life sciences industry.

For more information, visit: www.early-health.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/006fb975-2551-4209-85ab-c0bea47c4a90


Dr. Danny Renout 
Chief Executive Officer
d.renout@early-health.com
+971 50 980 6681

Dr. Andreas Nechansky 
Chief Executive Officer
a.nechansky@vela-labs.at
+43 699 1314 3112

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.